Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial by Bonnita Werner, Katrin M Sjoquist, David Espinoza, Sonia Yip, Garry Chang, Michelle M Cummins, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Michael Friedlander, Kristina Warton, Caroline E. Ford

Get full text

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial by Chris Brown, Nick Pavlakis, Patrick M Forde, Julie Brahmer, Suresh Ramalingam, Valsamo Anagnostou, Brett Hughes, Martin Stockler, Anna K Nowak, Sonia Yip, Peey Sei Kok, Zhuoxin Sun, Alistair Cook, Willem Joost Lesterhuis, Ken O’Byrne, Kate Ford, Karen Fitzpatrick, Alison Bricker, Michelle M Cummins

Get full text

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE) by Chee Khoon Lee, PhD, Bin-Chi Liao, MD, Shalini Subramaniam, MMed (Clin Epi), Chao-Hua Chiu, MD, Antony J. Mersiades, MMed (Clin Epi), Chao-Chi Ho, MD, PhD, Chris Brown, MBiostats, Chun-Liang Lai, MD, PhD, Brett G.M. Hughes, M.B.B.S. (Hons), Tsung-Ying Yang, MD, PhD, Ken O’Byrne, MD, Yung-Hung Luo, MD, PhD, Sonia Yip, PhD, Ching-Liang Ho, MD, Victoria Bray, PhD, Wu-Chou Su, MD, PhD, Melissa Moore, PhD, Wei-Lien Feng, MS, Ya-Ying Bai, MS, Kate Ford, MHSc, Michelle M. Cummins, PhD, Martin R. Stockler, MSc (Clin Epi), Benjamin J. Solomon, PhD, Thomas John, PhD, James Chih-Hsin Yang, MD, PhD

Get full text